Administration of Intravenous NRX100 (Ketamine) vs Placebo Infusion for Rapid Stabilization of Acute Suicidal Ideation and Behavior in Patients With Bipolar Depression

Trial Profile

Administration of Intravenous NRX100 (Ketamine) vs Placebo Infusion for Rapid Stabilization of Acute Suicidal Ideation and Behavior in Patients With Bipolar Depression

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 21 Mar 2018

At a glance

  • Drugs Cycloserine/lurasidone (Primary)
  • Indications Bipolar depression
  • Focus Registrational; Therapeutic Use
  • Acronyms SevereBD
  • Sponsors NeuroRX
  • Most Recent Events

    • 16 Mar 2018 Planned initiation date changed from 27 Jan 2018 to 1 May 2018.
    • 16 Jan 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top